Developer docs
API playgroundTry for free, no card

Search company profiles

Monument Therapeutics

Full company profile

uuid0000pw2

Namestring
Monument Therapeutics
Legal namestring
Monument Therapeutics Limited
Websiteurl
monumenttx.com
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMacclesfield, United Kingdom
HQ citystring
Macclesfield
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision neuroscience therapeutics, digital biomarker stratification, CNS drug development, schizophrenia treatment research, neuroinflammation therapeutics
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Health Services8000
Product category
CNS Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development
TypeOne Time License
Description

Developing novel CNS therapeutics through clinical development toward regulatory approval and commercialization. Revenue will be generated through product sales or licensing agreements upon successful development.

monumenttx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Monument Therapeutics is a clinical-stage biotech developing two CNS drug programs: MT1988, a fixed-dose combination of tropisetron and varenicline for cognitive impairment associated with schizophrenia (CIAS), and MT1980, a LipiCore-formulated anti-inflammatory compound for neuroinflammation conditions including Alzheimer's disease, post-operative cognitive dysfunction, and Long COVID. The company pairs these drug candidates with proprietary digital cognitive biomarkers (latent inhibition) and licensed CANTAB assessments to stratify patients and match them to targeted treatments.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Monument Therapeutics is a UK clinical-stage biotech company developing a pipeline of two core drug treatments for psychiatric and neurological conditions. The lead program MT1988 is a fixed-dose combination of tropisetron and varenicline targeting cognitive impairment associated with schizophrenia, using proprietary digital biomarkers for patient stratification. The second program MT1980 is an anti-neuroinflammatory compound using licensed LipiCore drug delivery technology for neuroinflammation-related conditions. The company leverages proprietary cognitive assessment tools (including latent inhibition tasks) alongside licensed CANTAB assessments from Cambridge Cognition to match patients with targeted treatments.

Product and service2 records
1MT1988
CategoryCNS Therapeutics — Schizophrenia
Description

MT1988 is a novel fixed-dose combination of tropisetron (α7 nAChR partial agonist, 5-HT3 antagonist) and varenicline (α7/α4β2 agonist, 5-HT3 agonist) being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS). Designed to enhance cognitive function while counteracting peripheral GI side effects, MT1988 is intended for use alongside existing antipsychotic medications. Patient selection is guided by Monument's proprietary latent-inhibition digital cognitive biomarker. Composition-of-matter patents are granted in the US, UK, Japan, and China with exclusivity extending to 2040-2042.

2MT1980
CategoryCNS Therapeutics — Neuroinflammation
Description

MT1980 is a lipid-based reformulation of an on-market anti-inflammatory compound using LipiCore drug delivery technology licensed from TRx Biosciences. The LipiCore formulation is designed to enable the compound to cross the blood-brain barrier, addressing penetration limitations of standard formulations. MT1980 is being developed for neuroinflammation-associated indications including Alzheimer's disease, post-operative cognitive dysfunction (POCD), stroke, traumatic brain injury, depression, and Long COVID. UK patent protection extends to at least 2044.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierProgramTypeGTM or Marketing PartnerAnnounced on2026-02-09
Description

Selected for 2026 One Mind Accelerator cohort (4th cohort since 2023) focused on mental health innovation with less than 5% acceptance rate. Prior portfolio companies raised nearly $1 billion and impacted 1 million people since Demo Day.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-08-19
Description

Partnership with FNIH to evaluate MT1988 in proof-of-principle clinical trial as part of the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. Trial enrolls 150 CHR participants at 15 US sites over 8-week treatment period, evaluating cognitive symptoms and biomarkers including proprietary digital biomarker. Supported by NIH grants to Yale and Brigham and Women's Hospital totaling $44 million.

Strategic tierClinical TrialTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-11-26
Description

Phase I clinical trial Principal Investigator site for MT1988 evaluation of safety, tolerability and pharmacokinetics in healthy adults.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-06-13
Description

Licensed LipiCore targeted oral drug delivery technology for MT1980 to solve blood-brain barrier penetration limitations. Technology enables anti-inflammatory compounds to access the CNS for neuroinflammation treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-20
Description

Preclinical collaboration for MT1988 program with School of Psychology including Professor Claire Gibson and Dr Stuart Williams. Provided preclinical proof of mechanism evidence for biomarker and drug combination prior to clinical trials.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-07-01
Description

Spin-out from Cambridge Cognition with minority shareholding retained. Licensed gold-standard cognitive assessments including CANTAB for patient stratification. Monument commercializes digital biomarkers across neuroscience indications with Cambridge Cognition retaining IP.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1BlackThorn Therapeutics
TypeDirect peer
Description

Precision neuroscience company applying computational approaches and digital biomarkers to CNS drug development, with programs in depression and other psychiatric conditions. Directly comparable precision psychiatry approach using patient stratification.

TypeDirect peer
Description

Clinical-stage precision psychiatry company using biomarkers (including EEG and digital measures) to stratify patients and match them with targeted CNS therapeutics, including for schizophrenia. Most directly comparable to Monument on the digital biomarker + targeted CNS drug model.

TypeDirect peer
Description

Developed xanomeline-trospium (Cobenfy) for schizophrenia, approved 2024 and acquired by Bristol Myers Squibb. Directly comparable CNS precision therapeutics company that successfully advanced a targeted schizophrenia therapy through pivotal trials.

TypeEmerging player
Description

Clinical-stage mental health company developing psilocybin-based therapeutics for treatment-resistant depression and other psychiatric conditions. Comparable as a CNS-focused clinical-stage biotech pursuing novel mechanisms in psychiatry.

TypeBroad incumbent
Description

Established commercial CNS specialty pharma (Nuplazid, Daybue) with schizophrenia and neurology pipeline. Provides an incumbent comparison point for Monument's specialty CNS commercial pathway.

TypeDirect peer
Description

CNS-focused company developing therapeutics for schizophrenia, depression, and other brain disorders (Zurzuvae, collaboration with Biogen). Directly comparable specialty CNS biotech with late-stage clinical pipeline.

TypeDirect peer
Description

Precision neuroscience company (acquired by AbbVie in 2024 for ~$8.7B) with a pipeline including emraclidine for schizophrenia. Directly comparable CNS precision therapeutics developer targeting similar patient subpopulations.

TypeBroad incumbent
Description

CNS specialty pharma (Caplyta/lumateperone for schizophrenia and bipolar depression, acquired by J&J in 2025). Established specialty CNS player operating in Monument's target indications.

TypeDirect peer
Description

Clinical-stage precision neuroscience company developing targeted therapies for brain diseases using data-driven patient stratification. Closely aligned with Monument's biomarker-driven precision psychiatry thesis.

10Boehringer Ingelheim (CNS)
TypeBroad incumbent
Description

Large pharmaceutical company with active CNS pipeline including schizophrenia programs (e.g., iclepertin for CIAS) and is a potential strategic acquirer / licensing partner for clinical-stage CNS assets like Monument's MT1988.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Monument Therapeutics

CNS Therapeuticsmonumenttx.com

Monument Therapeutics firmographics

Firmographics
Name
Monument Therapeutics
Legal name
Monument Therapeutics Limited
Website
https://monumenttx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Monument Therapeutics industry classification

Industry
Product category
CNS Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Precision neuroscience therapeutics
  • Digital biomarker stratification
  • CNS drug development
  • Schizophrenia treatment research
  • Neuroinflammation therapeutics

Where Monument Therapeutics is headquartered

Location

Headquarters

HQ city
Macclesfield
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Monument Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Development: Developing novel CNS therapeutics through clinical development toward regulatory approval and commercialization. Revenue will be generated through product sales or licensing agreements upon successful development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Monument Therapeutics product offering

Product offering

Core offering

Monument Therapeutics is a clinical-stage biotech developing two CNS drug programs: MT1988, a fixed-dose combination of tropisetron and varenicline for cognitive impairment associated with schizophrenia (CIAS), and MT1980, a LipiCore-formulated anti-inflammatory compound for neuroinflammation conditions including Alzheimer's disease, post-operative cognitive dysfunction, and Long COVID. The company pairs these drug candidates with proprietary digital cognitive biomarkers (latent inhibition) and licensed CANTAB assessments to stratify patients and match them to targeted treatments.

Product overview

Monument Therapeutics is a UK clinical-stage biotech company developing a pipeline of two core drug treatments for psychiatric and neurological conditions. The lead program MT1988 is a fixed-dose combination of tropisetron and varenicline targeting cognitive impairment associated with schizophrenia, using proprietary digital biomarkers for patient stratification. The second program MT1980 is an anti-neuroinflammatory compound using licensed LipiCore drug delivery technology for neuroinflammation-related conditions. The company leverages proprietary cognitive assessment tools (including latent inhibition tasks) alongside licensed CANTAB assessments from Cambridge Cognition to match patients with targeted treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • MT1988 MT1988 is a novel fixed-dose combination of tropisetron (α7 nAChR partial agonist, 5-HT3 antagonist) and varenicline (α7/α4β2 agonist, 5-HT3 agonist) being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS). Designed to enhance cognitive function while counteracting peripheral GI side effects, MT1988 is intended for use alongside existing antipsychotic medications. Patient selection is guided by Monument's proprietary latent-inhibition digital cognitive biomarker. Composition-of-matter patents are granted in the US, UK, Japan, and China with exclusivity extending to 2040-2042.
  • MT1980 MT1980 is a lipid-based reformulation of an on-market anti-inflammatory compound using LipiCore drug delivery technology licensed from TRx Biosciences. The LipiCore formulation is designed to enable the compound to cross the blood-brain barrier, addressing penetration limitations of standard formulations. MT1980 is being developed for neuroinflammation-associated indications including Alzheimer's disease, post-operative cognitive dysfunction (POCD), stroke, traumatic brain injury, depression, and Long COVID. UK patent protection extends to at least 2044.

Companies that use Monument Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Monument Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Monument Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered program, flagship, clinical trial and core.

  • One Mind AcceleratorprogramGTM or Marketing Partner · 9 February 2026Selected for 2026 One Mind Accelerator cohort (4th cohort since 2023) focused on mental health innovation with less than 5% acceptance rate. Prior portfolio companies raised nearly $1 billion and impacted 1 million people since Demo Day.
  • Foundation for the National Institutes of Health (FNIH)flagshipStrategic or Co-development Partner · 19 August 2025Partnership with FNIH to evaluate MT1988 in proof-of-principle clinical trial as part of the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. Trial enrolls 150 CHR participants at 15 US sites over 8-week treatment period, evaluating cognitive symptoms and biomarkers including proprietary digital biomarker. Supported by NIH grants to Yale and Brigham and Women's Hospital totaling $44 million.
  • BDD Pharmaclinical trialImplementation/ SI/ Consulting Partner · 26 November 2024Phase I clinical trial Principal Investigator site for MT1988 evaluation of safety, tolerability and pharmacokinetics in healthy adults.
  • TRx BiosciencescoreTechnology or Integration · 13 June 2022Licensed LipiCore targeted oral drug delivery technology for MT1980 to solve blood-brain barrier penetration limitations. Technology enables anti-inflammatory compounds to access the CNS for neuroinflammation treatment.
  • University of NottinghamcoreStrategic or Co-development Partner · 20 September 2021Preclinical collaboration for MT1988 program with School of Psychology including Professor Claire Gibson and Dr Stuart Williams. Provided preclinical proof of mechanism evidence for biomarker and drug combination prior to clinical trials.
  • Cambridge CognitioncoreTechnology or Integration · 1 July 2021Spin-out from Cambridge Cognition with minority shareholding retained. Licensed gold-standard cognitive assessments including CANTAB for patient stratification. Monument commercializes digital biomarkers across neuroscience indications with Cambridge Cognition retaining IP.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

Monument Therapeutics competitors and assessment

Company assessment

Direct peers

  • BlackThorn Therapeutics: Precision neuroscience company applying computational approaches and digital biomarkers to CNS drug development, with programs in depression and other psychiatric conditions. Directly comparable precision psychiatry approach using patient stratification.
  • Alto Neuroscience: Clinical-stage precision psychiatry company using biomarkers (including EEG and digital measures) to stratify patients and match them with targeted CNS therapeutics, including for schizophrenia. Most directly comparable to Monument on the digital biomarker + targeted CNS drug model.
  • Karuna Therapeutics: Developed xanomeline-trospium (Cobenfy) for schizophrenia, approved 2024 and acquired by Bristol Myers Squibb. Directly comparable CNS precision therapeutics company that successfully advanced a targeted schizophrenia therapy through pivotal trials.
  • Sage Therapeutics: CNS-focused company developing therapeutics for schizophrenia, depression, and other brain disorders (Zurzuvae, collaboration with Biogen). Directly comparable specialty CNS biotech with late-stage clinical pipeline.
  • Cerevel Therapeutics: Precision neuroscience company (acquired by AbbVie in 2024 for ~$8.7B) with a pipeline including emraclidine for schizophrenia. Directly comparable CNS precision therapeutics developer targeting similar patient subpopulations.
  • Neumora Therapeutics: Clinical-stage precision neuroscience company developing targeted therapies for brain diseases using data-driven patient stratification. Closely aligned with Monument's biomarker-driven precision psychiatry thesis.

Emerging players

  • Compass Pathways: Clinical-stage mental health company developing psilocybin-based therapeutics for treatment-resistant depression and other psychiatric conditions. Comparable as a CNS-focused clinical-stage biotech pursuing novel mechanisms in psychiatry.

Broad incumbents

  • Acadia Pharmaceuticals: Established commercial CNS specialty pharma (Nuplazid, Daybue) with schizophrenia and neurology pipeline. Provides an incumbent comparison point for Monument's specialty CNS commercial pathway.
  • Intra-Cellular Therapies: CNS specialty pharma (Caplyta/lumateperone for schizophrenia and bipolar depression, acquired by J&J in 2025). Established specialty CNS player operating in Monument's target indications.
  • Boehringer Ingelheim (CNS): Large pharmaceutical company with active CNS pipeline including schizophrenia programs (e.g., iclepertin for CIAS) and is a potential strategic acquirer / licensing partner for clinical-stage CNS assets like Monument's MT1988.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Monument Therapeutics social profiles

Digital presence

Monument Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Monument Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Monument Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Monument Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Monument Therapeutics

What does Monument Therapeutics do?

Monument Therapeutics is a clinical-stage biotech developing two CNS drug programs: MT1988, a fixed-dose combination of tropisetron and varenicline for cognitive impairment associated with schizophrenia (CIAS), and MT1980, a LipiCore-formulated anti-inflammatory compound for neuroinflammation conditions including Alzheimer's disease, post-operative cognitive dysfunction, and Long COVID. The company pairs these drug candidates with proprietary digital cognitive biomarkers (latent inhibition) and licensed CANTAB assessments to stratify patients and match them to targeted treatments.

Is Monument Therapeutics a public or private company?

Monument Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Monument Therapeutics founded?

Monument Therapeutics was founded in 2021. It employs 1 to 10 people.

Where is Monument Therapeutics based?

Monument Therapeutics is headquartered in Macclesfield, United Kingdom, in the Europe region.

How does Monument Therapeutics make money?

One revenue line is on record: pharmaceutical Drug Development.

Who are Monument Therapeutics's main competitors?

Direct peers on record are BlackThorn Therapeutics, Alto Neuroscience, Karuna Therapeutics, Sage Therapeutics, Cerevel Therapeutics and Neumora Therapeutics. Compass Pathways is listed as an emerging player. Broad incumbents are Acadia Pharmaceuticals, Intra-Cellular Therapies and Boehringer Ingelheim (CNS).

Does Monument Therapeutics have an API?

No public API is recorded for Monument Therapeutics.

What industry is Monument Therapeutics in?

Monument Therapeutics's product category is CNS Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireMonument Tx Announces US Patent for MT1988, a Novel Treatment for Cognitive Impairment Associated with SchizophreniaMonument Therapeutics announced the USPTO granted a patent for MT1988, a fixed-dose combination for cognitive impairment in schizophrenia, with exclusivity until 2042. The drug is in a proof-of-principle trial at 15 U.S. sites, the first patient study from its precision medicine pipeline.PharmiWeb.comCambridge Cognition Investment, Monument Therapeutics, Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for PsychosisCambridge Cognition and Monument Therapeutics announced the first patient dosing in a clinical trial for MT1988, a potential treatment for patients at high risk for psychosis. The trial aims to evaluate cognitive improvements and biomarker responses over eight weeks with 150 participants.EIN PresswireMonument Therapeutics Announces First Patient Dosed in Trial of MT1988 in Patients at Clinical High Risk for PsychosisMonument Therapeutics announced that the first patient has been dosed in its proof-of-principle clinical trial of MT1988 in patients at clinical high risk (CHR) for psychosis. The randomized, placebo-controlled study will enroll 150 participants who will receive one of two dose levels of MT1988 or placebo over an eight-week treatment period, and is being conducted in collaboration with the Foundation for the National Institutes of Health (FNIH) as part of the Accelerating Medicines Partnership Schizophrenia program. There are currently no approved pharmacological treatments for the CHR population, making this early-intervention trial a significant step in developing new therapeutic options for people at risk of schizophrenia.PR NewswireMonument Therapeutics Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for SchizophreniaMonument Therapeutics announced a partnership with the Foundation for the National Institutes of Health to conduct a proof-of-principle clinical trial evaluating MT1988, a novel treatment for cognitive impairment associated with schizophrenia, enrolling 150 clinical high-risk participants in a randomized, placebo-controlled study expected to begin dosing in autumn 2025. The trial is the first patient trial from Monument's precision medicine pipeline and will incorporate the company's proprietary digital biomarker to assess treatment response. The study is part of the FNIH-managed Accelerating Medicines Partnership Schizophrenia program, which has received $44 million in NIH grant funding.PR NewswireMonument Therapeutics Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for SchizophreniaMonument Therapeutics announced a partnership with the Foundation for the National Institutes of Health to evaluate MT1988, a novel treatment for cognitive impairment in schizophrenia, in a proof-of-principle trial. The randomized, placebo-controlled study will enroll 150 clinical high-risk participants over eight weeks, with dosing expected in autumn 2025. The trial is part of the AMP SCZ program, supported by a $44 million NIH investment.YahooMonument Therapeutics Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for SchizophreniaMonument Therapeutics announced a partnership with the Foundation for the National Institutes of Health to evaluate MT1988, a novel treatment for cognitive impairment in schizophrenia, in a proof-of-principle trial. The randomized, placebo-controlled study will enroll 150 clinical high-risk participants over eight weeks, with dosing expected to begin in autumn 2025.PR NewswireMonument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory BoardMonument Therapeutics appointed Robert Radie as non-executive chair and Heather Preston to its advisory board. Radie brings over three decades of neuroscience experience, including leadership at Prestwick Pharmaceuticals and Zyla Life Sciences. Preston, a healthcare venture capitalist, previously served on Karuna Therapeutics' board.MonumenttxMonument Therapeutics Secures £850k to Advance Breakthrough Schizophrenia TreatmentMonument Therapeutics secured £850k in funding led by ACF Investors to advance its schizophrenia treatment MT1988. The drug targets cognitive impairment, with Phase 1 results expected in Q2 2025. The company aims to address unmet need for cognitive symptoms.Cambridge CognitionMonument Therapeutics secures £850k to advance breakthrough schizophrenia treatmentMonument Therapeutics secured £850k in funding led by ACF Investors to advance its schizophrenia treatment MT1988. The drug targets cognitive impairment, with Phase 1 results expected in Q2 2025. The company aims to address unmet need for cognitive symptoms.